title: Chemotherapy in metastatic malignant triton tumor: report on two cases.
abstract: Malignant triton tumor (MTT) is a rare, highly malignant nerve sheath tumor with rhabdomyoblastic differentiation. Initial debulking surgery followed by adjuvant therapy is the current treatment of choice, but has very limited efficacy when optimal cytoreduction is not achieved by surgical procedure. Neoadjuvant therapy for MTT, to potentially facilitate subsequent surgery, eradicate micrometastatic lesions and, therefore, improve the therapeutical outcome, has never before been presented in literature. Here, we report on the multimodal management of two cases of advanced and metastatic MTT. Treatment modalities involved neoadjuvant and adjuvant chemotherapy, surgical resection, and radiation. In both cases, integrated Positron Emission Tomography/Computed Tomography (PET/CT) emerged as an important diagnostic tool for the reliable assessment of MTT response and metabolic remission.
authors.affiliation: Department of Medicine, Hematology and Oncology, University of Münster, D-48149 Münster, Germany. n.thoennissen@gmx.de
authors.forename: N H
authors.initials: NH
authors.lastname: Thoennissen
authors.forename: C
authors.initials: C
authors.lastname: Schliemann
authors.forename: U
authors.initials: U
authors.lastname: Brunnberg
authors.forename: E
authors.initials: E
authors.lastname: Schmidt
authors.forename: A
authors.initials: A
authors.lastname: Staebler
authors.forename: L
authors.initials: L
authors.lastname: Stegger
authors.forename: C
authors.initials: C
authors.lastname: Bremer
authors.forename: C
authors.initials: C
authors.lastname: Schleicher
authors.forename: R M
authors.initials: RM
authors.lastname: Mesters
authors.forename: C
authors.initials: C
authors.lastname: Müller-Tidow
authors.forename: W E
authors.initials: WE
authors.lastname: Berdel
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002430:Cecal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007078:Ileal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D008297:Male; D020360:Neoadjuvant Therapy; D009442:Neurilemmoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D009456:Neurofibromatosis 1 / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*